Sinan Can Demir wanted to spend the last week of July burnishing his resume. Instead, he engaged in a battle with an artificial-intelligence agent unleashed by a British government lab.

ZUG, Switzerland, August 24th, 2026 -- (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ...